Aktis Oncology (NASDAQ:AKTS) Shares Down 7.1% – Here’s Why

Aktis Oncology (NASDAQ:AKTS) shares traded down 7.1% during mid-day trading on Friday . The stock traded as low as $20.32 and last traded at $20.80. 56,940 shares changed hands during trading, a decline of 84% from the average session volume of 367,310 shares. The stock had previously closed at $22.40.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th.

Aktis Oncology Price Performance

Insiders Place Their Bets

In other news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the insider directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were bought at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the purchase, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 6,117,776 shares of company stock valued at $110,119,968. Corporate insiders own 3.30% of the company’s stock.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.